IMAGINE

Innovative Science | Differentiated Therapies | Improved Outcomes

VIRTUAL KOL EVENT

Inhibition of the OX40/OX40L Signaling in the Treatment of Atopic Dermatitis and Alopecia Areata

THURSDAY, OCTOBER 31, 2024 | 10:00 AM ET

woman and man working - INMAGENE Bio

AT INMAGENE

We are pioneering a new generation of therapies with best-in-class potential across a spectrum of immunological and inflammatory diseases. Leveraging external innovation and our proprietary QuadraTek® platform, we are developing differentiated treatments that have the potential to offer better outcomes to patients.

Our science

Our lead candidates have been engineered to address a broad spectrum of immune and inflammatory indications while optimizing safety, efficacy, and convenience.

Pipeline

We are developing a new generation of therapies for patients living with immunologic and inflammatory diseases.

Partnerships

Join our mission to deliver better therapies to patients in need.

woman smiling - inmagene bio
Scroll to Top